Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 20
HOS-086303 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism,
Pravastatin, Rosuvastatin, Simvastatin such as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent
or as a pharmacokinetic enhancer. Since increased concentrations of lovastatin and
simvastatin may predispose patients to myopathies, including rhabdomyolysis, the
combination of these medicinal products with ritonavir is contraindicated (see
section 4.3). Atorvastatin is less dependent on CYP3A for metabolism. While
rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin
exposure has been reported with ritonavir co-administration. The mechanism of this
interaction is not clear, but may be the result of transporter inhibition. When used
with ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent, the
lowest possible doses of atorvastatin or rosuvastatin should be administered. The
metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and
interactions are not expected with ritonavir. If treatment with an HMG-CoA
reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) pravastatin (HOS-086306) rosuvastatin (HOS-086307) atorvastatin (HOS-086304) fluvastatin (HOS-086305) lovastatin (HOS-086157)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9aca472a9605d2ce92f2e3c73c3d58774cec61e0cad5a2ae7e9aa807365f0d07 · Zeichen 43147–44996 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-086472 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such
Pravstatin, Rosuvastatin, Simvastatin as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as
a pharmacokinetic enhancer. Since increased concentrations of lovastatin and simvastatin
may predispose patients to myopathies, including rhabdomyolysis, the combination of
these medicinal products with ritonavir is contraindicated (see section 4.3). Atorvastatin
is less dependent on CYP3A for metabolism. While rosuvastatin elimination is not
dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with
ritonavir co-administration. The mechanism of this interaction is not clear, but may be
the result of transporter inhibition. When used with ritonavir dosed as a pharmacokinetic
enhancer or as an antiretroviral agent, the lowest possible doses of atorvastatin or
rosuvastatin should be administered. The metabolism of pravastatin and fluvastatin is not
dependent on CYP3A, and interactions are not expected with ritonavir. If treatment with
an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) fluvastatin (HOS-086305) lovastatin (HOS-086157) rosuvastatin (HOS-086307) simvastatin (HOS-086158) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage aecf6db95f104726bea3f53130826841fcecb464a1fff5ff24afdad33e090079 · Zeichen 44359–46167 im Abschnitt
Wechselwirkungen · Plavix
Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-087963 · Präparat HOS-083591
Rosuvastatin: Clopidogrel has been shown to increase rosuvastatin exposure in patients by 2-fold
(AUC) and 1.3-fold (Cmax) after administration of a 300 mg clopidogrel dose, and by 1.4-fold (AUC)
without effect on Cmax after repeated administration of a 75 mg clopidogrel dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-14T12:15:00Z · SHA-256 1e6a9d1e2861882ccf51f6506686a24b3c88e112fad66a7a9333c6e88547592c · Passage dc38fd73366078ede689777f9af7807a20ec4d2f4676d48faae5e7c88f656a02 · Zeichen 9104–9381 im Abschnitt
Wechselwirkungen · Iscover
Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088012 · Präparat HOS-083599
Rosuvastatin: Clopidogrel has been shown to increase rosuvastatin exposure in patients by 2-fold
(AUC) and 1.3-fold (Cmax) after administration of a 300 mg clopidogrel dose, and by 1.4-fold (AUC)
without effect on Cmax after repeated administration of a 75 mg clopidogrel dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-26T11:41:00Z · SHA-256 3fe5799ec5f9f1d2b848168c6cfaf56d702c6bce3141e7d7aa95ef81abbc8acc · Passage dc38fd73366078ede689777f9af7807a20ec4d2f4676d48faae5e7c88f656a02 · Zeichen 9102–9379 im Abschnitt
Wechselwirkungen · Arava
Arava 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-089672 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) daunorubicin (HOS-089674) doxorubicin (HOS-084538) simvastatin (HOS-086158) atorvastatin (HOS-086304) pravastatin (HOS-086306) nateglinide (HOS-089675) repaglinide (HOS-086935) methotrexate (HOS-087522) topotecan (HOS-086047) rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5491–6465 im Abschnitt
Wechselwirkungen · Arava
Arava 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-089736 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) methotrexate (HOS-087522) topotecan (HOS-086047) sulfasalazine (HOS-089673) daunorubicin (HOS-089674) doxorubicin (HOS-084538) simvastatin (HOS-086158) atorvastatin (HOS-086304) pravastatin (HOS-086306) nateglinide (HOS-089675) repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5493–6467 im Abschnitt
Wechselwirkungen · Arava
Arava 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-089796 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methotrexate (HOS-087522) topotecan (HOS-086047) sulfasalazine (HOS-089673) daunorubicin (HOS-089674) doxorubicin (HOS-084538) simvastatin (HOS-086158) atorvastatin (HOS-086304) pravastatin (HOS-086306) nateglinide (HOS-089675) repaglinide (HOS-086935) rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5489–6463 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 24–25
HOS-108934 · Präparat HOS-093083
24
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended.
Cmax: ↑ 4.7-fold If the use of atorvastatin is
Due to CYP3A inhibition by considered strictly necessary, the
lopinavir/ritonavir. lowest possible dose of
atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be
Cmax: ↑ 5-fold considered when Kaletra is
While rosuvastatin is poorly co-administered with rosuvastatin
metabolised by CYP3A4, an (see section 4.4).
increase of its plasma
concentrations was observed.
The mechanism of this interaction
may result from inhibition of
transport proteins.
Fluvastatin or Pravastatin Fluvastatin, Pravastatin: If treatment with an HMG-CoA
No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg QD Buprenorphine: ↔ No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lomitapide (HOS-086160) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306) buprenorphine (HOS-086193)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a27011337575de5ab6a9cbb05a4ed667b9b72fba13fff3beebbce86283b037b · Zeichen 57600–59815 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-109022 · Präparat HOS-093083
59
Herbal products
St John’s wort Lopinavir: Herbal preparations containing St
(Hypericum perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels. Lopinavir
and ritonavir levels may increase on
stopping St John’s wort. The dose of
Kaletra may need adjusting. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s wort (see
section 4.3). Therefore, Kaletra can
be started safely 2 weeks after
cessation of St John's wort.
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors may
concentrations due to CYP3A cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest possible
lopinavir/ritonavir. dose of atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered with
While rosuvastatin is poorly rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin reductase inhibitor is indicated,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sirolimus (HOS-085172) tacrolimus (HOS-085202) lovastatin (HOS-086157) simvastatin (HOS-086158) lomitapide (HOS-086160) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 828eb1430737116e7e38afe94ac9495cef2e1489ddb625df82544aac21c48455 · Zeichen 52305–56991 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 95–96
HOS-109101 · Präparat HOS-093083
95
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest
lopinavir/ritonavir. possible dose of atorvastatin should
be administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered
While rosuvastatin is poorly with rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sirolimus (HOS-085172) tacrolimus (HOS-085202) lovastatin (HOS-086157) simvastatin (HOS-086158) lomitapide (HOS-086160) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306) buprenorphine (HOS-086193) methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8615aceaaf9aeead58e7d8428a116c5869ad8f9e57e471dff2f6359133eeb12b · Zeichen 55116–58920 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15–16
HOS-114832 · Präparat HOS-094169
15
Inhibition of CYP 3A4 by
tipranavir/r
HMG CoA reductase inhibitors
Atorvastatin 10 mg QD Atorvastatin Cmax ↑ 8.6 fold Co-administration of atorvastatin
Atorvastatin AUC ↑ 9.4 fold and Aptivus, co-administered
Atorvastatin Cmin ↑ 5.2 fold with low dose ritonavir, is not
recommended. Other HMG-CoA
Tipranavir ↔ reductase inhibitors should be
considered such as pravastatin,
Inhibition of CYP 3A4 by fluvastatin or rosuvastatin (See
tipranavir/r also section 4.4 and rosuvastatin
and pravastatin
recommendations). In cases
where co-administration is
necessary, the dose of 10 mg
atorvastatin daily should not be
exceeded. It is recommended to
start with the lowest dose and
careful clinical monitoring is
necessary (see section 4.4).
Rosuvastatin 10 mg QD Rosuvastatin Cmax ↑ 123% Co-administration of Aptivus, co-
Rosuvastatin AUC ↑ 37% administered with low dose
Rosuvastatin Cmin ↑ 6% ritonavir, and rosuvastatin should
be initiated with the lowest dose
Tipranavir ↔ (5 mg/day) of rosuvastatin,
titrated to treatment response, and
Mechanism unknown. accompanied with careful clinical
monitoring for rosuvastatin
associated symptoms as
described in the label of
rosuvastatin.
Pravastatin Based on similarities in the Co-administration of Aptivus, co-
No interaction study elimination between pravastatin administered with low dose
performed and rosuvastatin, TPV/r could ritonavir, and pravastatin should
increase the plasma levels of be initiated with the lowest dose
pravastatin. (10 mg/day) of pravastatin,
titrated to treatment response, and
Mechanism unknown. accompanied with careful clinical
monitoring for pravastatin
associated symptoms as
described in the label of
pravastatin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) ritonavir (HOS-084521) pravastatin (HOS-086306) fluvastatin (HOS-086305) rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 74f0f6a876d317957363e31e1c33f99584b8a000435d6c65678be0fe9ff9b411 · Zeichen 30010–33650 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 21–22
HOS-116415 · Präparat HOS-094447
21
Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of
10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and boosted
║
based on published data with PREZISTA is required, it is
darunavir/ritonavir recommended to start with the
lowest possible dose of
rosuvastatin AUC ↑ 93%§ rosuvastatin and titrate up to the
rosuvastatin Cmax ↑ 277%§ desired clinical effect while
rosuvastatin Cmin ND§ monitoring for safety.
§
with darunavir/cobicistat 800/150 mg
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical considerations Co-administration is
boosted PREZISTA is expected to contraindicated (see section 4.3).
increase the exposure of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Ranitidine # Boosted PREZISTA can be
darunavir AUC ↔
150 mg twice daily #
darunavir Cmin ↔ co-administered with H2-receptor
#
darunavir Cmax ↔ antagonists without dose
adjustments.
IMMUNOSUPPRESSANTS
Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the
Sirolimus immunosuppressants will be increased immunosuppressive agent must be
Tacrolimus when co-administered with boosted done when co-administration
PREZISTA. occurs.
(CYP3A inhibition)
Everolimus Concomitant use of everolimus
and boosted PREZISTA is not
recommended.
INHALED BETA AGONISTS
Salmeterol Not studied. Concomitant use of Concomitant use of salmeterol and
salmeterol and boosted darunavir may boosted PREZISTA is not
increase plasma concentrations of recommended. The combination
salmeterol. may result in increased risk of
cardiovascular adverse event with
salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone
individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating
from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with boosted
once daily PREZISTA. However, adjustment
PREZISTA/cobicistat may, in contrast, of the methadone dose may be
increase methadone plasma necessary when concomitantly
concentrations (see cobicistat SmPC). administered for a longer period of
time. Therefore, clinical
monitoring is recommended, as
maintenance therapy may need to
be adjusted in some patients.
Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the
8/2 mg–16/4 mg once buprenorphine Cmin ↔ increase in norbuprenorphine
daily buprenorphine Cmax ↓ 8% pharmacokinetic parameters has
norbuprenorphine AUC ↑ 46% not been established. Dose
norbuprenorphine Cmin ↑ 71% adjustment for buprenorphine may
norbuprenorphine Cmax ↑ 36% not be necessary when
naloxone AUC ↔ co-administered with boosted
PREZISTA but a careful clinical
naloxone Cmin ND
monitoring for signs of opiate
naloxone Cmax ↔ toxicity is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) ritonavir (HOS-084521) cobicistat (HOS-088111) lomitapide (HOS-086160) ranitidine (HOS-085660) sirolimus (HOS-085172) tacrolimus (HOS-085202) everolimus (HOS-086310) salmeterol (HOS-086285) methadone (HOS-086198) buprenorphine (HOS-086193) naloxone (HOS-109490)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 5acbdf6c1f8cbcfa7417e6f43148a46845265b80041528b8854960cce50aae89 · Zeichen 63548–68815 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 63–64
HOS-116529 · Präparat HOS-094447
63
Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of
10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and PREZISTA
║
based on published data with co-administered with low dose
darunavir/ritonavir ritonavir is required, it is
recommended to start with the
lowest possible dose of
rosuvastatin and titrate up to the
desired clinical effect while
monitoring for safety.
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical considerations Co-administration is
boosted PREZISTA is expected to contraindicated (see section 4.3).
increase the exposure of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Ranitidine # PREZISTA co-administered with
darunavir AUC ↔
150 mg twice daily #
darunavir Cmin ↔ low dose ritonavir can be
#
darunavir Cmax ↔ co-administered with H2-receptor
antagonists without dose
adjustments.
IMMUNOSUPPRESSANTS
Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the
Sirolimus immunosuppressants will be increased immunosuppressive agent must be
Tacrolimus when co-administered with PREZISTA done when co-administration
co-administered with low dose ritonavir. occurs.
(CYP3A inhibition)
Everolimus Concomitant use of everolimus
and PREZISTA co-administered
with low dose ritonavir is not
recommended.
INHALED BETA AGONISTS
Salmeterol Not studied. Concomitant use ofConcomitant use of salmeterol and
salmeterol and darunavir co-administered
PREZISTA co-administered with
with low dose ritonavir may increase
low dose ritonavir is not
plasma concentrations of salmeterol.
recommended. The combination
may result in increased risk of
cardiovascular adverse event with
salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone
individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating
from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with
once daily PREZISTA/ritonavir. However,
increased methadone dose may be
necessary when concomitantly
administered for a longer period of
time due to induction of
metabolism by ritonavir.
Therefore, clinical monitoring is
recommended, as maintenance
therapy may need to be adjusted in
some patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660) sirolimus (HOS-085172) rosuvastatin (HOS-086307) ritonavir (HOS-084521) lomitapide (HOS-086160) tacrolimus (HOS-085202) everolimus (HOS-086310) salmeterol (HOS-086285) methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f2f65869b04ef808ebdc5d5e920ff573b17a50545ae43721f20f184c9d93d8d0 · Zeichen 54354–58869 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 103–104
HOS-116619 · Präparat HOS-094447
103
Rosuvastatin rosuvastatin AUC ↑ 48%║ When administration of
10 mg once daily rosuvastatin Cmax ↑ 144%║ rosuvastatin and boosted
║
based on published data with PREZISTA is required, it is
darunavir/ritonavir recommended to start with the
lowest possible dose of
rosuvastatin AUC ↑ 93%§ rosuvastatin and titrate up to the
rosuvastatin Cmax ↑ 277%§ desired clinical effect while
rosuvastatin Cmin ND§ monitoring for safety.
§
with darunavir/cobicistat 800/150 mg
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical considerations Co-administration is
boosted PREZISTA is expected to contraindicated (see section 4.3).
increase the exposure of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Ranitidine # Boosted PREZISTA can be
darunavir AUC ↔
150 mg twice daily #
darunavir Cmin ↔ co-administered with H2-receptor
#
darunavir Cmax ↔ antagonists without dose
adjustments.
IMMUNOSUPPRESSANTS
Ciclosporin Not studied. Exposure to these Therapeutic drug monitoring of the
Sirolimus immunosuppressants will be increased immunosuppressive agent must be
Tacrolimus when co-administered with boosted done when co-administration
PREZISTA. occurs.
(CYP3A inhibition)
Everolimus Concomitant use of everolimus
and boosted PREZISTA is not
recommended.
INHALED BETA AGONISTS
Salmeterol Not studied. Concomitant use of Concomitant use of salmeterol and
salmeterol and boosted darunavir may boosted PREZISTA is not
increase plasma concentrations of recommended. The combination
salmeterol. may result in increased risk of
cardiovascular adverse event with
salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
Methadone R(-) methadone AUC ↓ 16% No adjustment of methadone
individual dose ranging R(-) methadone Cmin ↓ 15% dosage is required when initiating
from 55 mg to 150 mg R(-) methadone Cmax ↓ 24% co-administration with boosted
once daily PREZISTA. However, adjustment
PREZISTA/cobicistat may, in contrast, of the methadone dose may be
increase methadone plasma necessary when concomitantly
concentrations (see cobicistat SmPC). administered for a longer period of
time. Therefore, clinical
monitoring is recommended, as
maintenance therapy may need to
be adjusted in some patients.
Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the
8/2 mg–16/4 mg once buprenorphine Cmin ↔ increase in norbuprenorphine
daily buprenorphine Cmax ↓ 8% pharmacokinetic parameters has
norbuprenorphine AUC ↑ 46% not been established. Dose
norbuprenorphine Cmin ↑ 71% adjustment for buprenorphine may
norbuprenorphine Cmax ↑ 36% not be necessary when
naloxone AUC ↔ co-administered with boosted
PREZISTA but a careful clinical
naloxone Cmin ND
monitoring for signs of opiate
naloxone Cmax ↔ toxicity is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) ritonavir (HOS-084521) cobicistat (HOS-088111) lomitapide (HOS-086160) ranitidine (HOS-085660) sirolimus (HOS-085172) tacrolimus (HOS-085202) everolimus (HOS-086310) salmeterol (HOS-086285) methadone (HOS-086198) buprenorphine (HOS-086193) naloxone (HOS-109490)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6e9aabce398149840c7621950bc6562a692bbfc641caaabe022d97e86d869ebf · Zeichen 62955–68223 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-119741 · Präparat HOS-095005
12
OESTROGEN-BASED CONTRACEPTIVES
Ethinylestradiol ethinylestradiol The combination of
0.035 mg once daily AUC ↑ 1.22 (1.13-1.31) oestrogen- and/or
Norethindrone Cmin ↔ 1.09 (1.01-1.18) progesterone-based
1 mg once daily Cmax ↑ 1.33 (1.21-1.46) contraceptives and
norethindrone INTELENCE can be used
AUC ↔ 0.95 (0.90-0.99) without dose adjustment.
Cmin ↓ 0.78 (0.68-0.90)
Cmax ↔ 1.05 (0.98-1.12)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
Ribavirin Not studied, but no interaction expected based The combination of
on the renal elimination pathway of ribavirin. INTELENCE and ribavirin
can be used without dose
adjustments.
Daclatasvir Not studied. Co-administration of etravirine Co-administration of
with daclatasvir may decrease daclatasvir INTELENCE and daclatasvir
concentrations. is not recommended.
Elbasvir/grazoprevir Not studied. Co-administration of etravirine Co-administration is
with elbasvir/grazoprevir may decrease elbasvir contraindicated (see
and grazoprevir concentrations, leading to section 4.3).
reduced therapeutic effect of
elbasvir/grazoprevir.
HERBAL PRODUCTS
St John’s wort Not studied. St John’s wort is expected to Combination not
(Hypericum perforatum)
decrease the plasma concentrations of recommended.
etravirine.
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin atorvastatin The combination of
40 mg once daily AUC ↓ 0.63 (0.58-0.68) INTELENCE and
Cmin ND atorvastatin can be given
Cmax ↑ 1.04 (0.84-1.30) without any dose
2-OH-atorvastatin adjustments, however, the
AUC ↑ 1.27 (1.19-1.36) dose of atorvastatin may
Cmin ND need to be altered based on
Cmax ↑ 1.76 (1.60-1.94) clinical response.
etravirine
AUC ↔ 1.02 (0.97-1.07)
Cmin ↔ 1.10 (1.02-1.19)
Cmax ↔ 0.97 (0.93-1.02)
Fluvastatin Not studied. No interaction between pravastatin Dose adjustments for these
Lovastatin and etravirine is expected. HMG Co-A reductase
Pravastatin Lovastatin, rosuvastatin and simvastatin are inhibitors may be necessary.
Rosuvastatin CYP3A4 substrates and co-administration with
Simvastatin etravirine may result in lower plasma
concentrations of the HMG Co-A reductase
inhibitor. Fluvastatin, and rosuvastatin are
metabolised by CYP2C9 and co-administration
with etravirine may result in higher plasma
concentrations of the HMG Co-A reductase
inhibitor.
H2-RECEPTOR ANTAGONISTS
Ranitidine etravirine INTELENCE can be
150 mg twice daily AUC ↓ 0.86 (0.76-0.97) co-administered with
Cmin ND H2-receptor antagonists
Cmax ↓ 0.94 (0.75-1.17) without dose adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): hepatitis C virus (HOS-108813) norethindrone (HOS-088136) ribavirin (HOS-088127) daclatasvir (HOS-119742) elbasvir (HOS-108814) grazoprevir (HOS-108815) atorvastatin (HOS-086304) fluvastatin (HOS-086305) pravastatin (HOS-086306) lovastatin (HOS-086157) rosuvastatin (HOS-086307) simvastatin (HOS-086158) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage b4ae62f3b56de12cf8406dcb55d38bc3538cd806a08b537965c6bb7ead0cc339 · Zeichen 24913–29265 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 200 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-120836 · Präparat HOS-095225
Rosuvastatin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 695909dac4b9f3dc4491b977fad156471217e9e17ddabbec6e725ce896ddafbf · Zeichen 5039–5051 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 200 mg tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-120837 · Präparat HOS-095225
6
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage fa6d27cbc82a21288339e4f7f46bb93471086af14bcf8331561e4329f38445f9 · Zeichen 5105–5587 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 400 mg tablets · Abschnitt 4.5 · PDF-Seite 24–25
HOS-120879 · Präparat HOS-095225
Simvastatin
A study in healthy subjects showed an average decrease of 50% in systemic exposure to simvastatin
when co-administered with eslicarbazepine acetate 800 mg once daily, most likely caused by an
induction of CYP3A4. An increase of the simvastatin dose may be required when used concomitantly
with eslicarbazepine acetate.
24
Rosuvastatin
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 06f36e0e97255f9961271f760b71fb84ff4600381544db3887bc1ba99160bf77 · Zeichen 4707–5585 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 600 mg tablets · Abschnitt 4.5 · PDF-Seite 42
HOS-120919 · Präparat HOS-095225
Rosuvastatin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 695909dac4b9f3dc4491b977fad156471217e9e17ddabbec6e725ce896ddafbf · Zeichen 5038–5050 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 600 mg tablets · Abschnitt 4.5 · PDF-Seite 42–43
HOS-120920 · Präparat HOS-095225
42
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage a362260269dab7484f56ceea007d350fe37dda64c9af71e77dc759d69fc2f0e1 · Zeichen 5104–5587 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.